Cancer immunotherapy

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage […]

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories:  Experimental immunotherapy has over 70% response rate  An immunotherapy that uses a new […]

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase II trial data for talquetamab, the company presented promising findings on the long-term results […]

An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials.  The trial results have been revealed by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.  The therapy, known as a bispecific […]

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not respond to them. Neobe was founded by Pedro […]

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded.  The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and immune response in the tissue environment that nurtures […]

Triumvira Immunologics has revealed positive clinical data from its ongoing TACTIC‑2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours.  These interim data demonstrate that TAC01-HER2 is well-tolerated and clinical activity was observed in the two higher dosing cohorts, with a 67% disease control rate in cohort […]

DynamiCure has dosed the first patients in its Phase I clinical trial evaluating the first of the company’s two anti-CD93 monoclonal antibody candidates, DCBY02, in adults with a wide range of advanced cancers.  CD93 is a novel target downstream of VEGF-A (vascular endothelial growth factor) that has been shown to play a critical role in […]

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.    The researchers found that intravenous (IV) administration of the vaccine SNAPvax boosted the number of cytotoxic T cells […]

Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D and therapeutics continue to spring up all around the globe, often spun out of universities working on the latest […]